[Intraarterial infusion therapy for unresectable liver metastasis of colorectal cancer].
Forty-two colorectal carcinomas with metastatic liver tumor at four hospitals were investigated retrospectively. The number of patients in H factor 1, 2 and 3 were 8, 12 and 21, respectively. The diameter of the maximum liver tumor ranged from 10 to 160 mm (average 45 mm). The number of liver tumors were from 1 to 50 (average 7.3). The 6-, 12-, 18-, 24- and 32-month cumulative survival rates were 88, 67, 36, 24%, and 7%, respectively. The response rate reached 45%, and the survival period of the responder was significantly more prolonged than that of the unresponder (p = 0.04). No significant survival periods were recognized in terms of the method of injection, injected drug and the amounts of 5-FU. But the response rate of FP injection was best. Patients serum CEA levels at 1 or 3 months were decreased, and the survival periods were significantly longer than for increased patients. No significant difference was found among the side effects, the amounts of 5-FU, and the method of injection. The patients injected with MMC frequently suffered from G 2 or G 3 side effects.
Ukei
T
T
Dept. of Surgery, Kinki Central Hospital.
Touno
T
T
Oozato
H
H
Yamamoto
H
H
Fukuda
K
K
D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D015179:Colorectal Neoplasms / Q000473:pathology*; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D012189:Retrospective Studies; D015996:Survival Rate
D000964:Antimetabolites, Antineoplastic; D016685:Mitomycin; D005472:Fluorouracil